AM-095

N/A

Report date: 2021/12/07 16:28:46
NME

Base Information

Drug NameAM-095
Drug Alias NameAM-095
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAmira Pharmaceuticals IncBristol-Myers Squibb Spa
China Registration ClassN/A

Develop Information

Active CompaniesGachon University
Inactive CompaniesN/A
Active IndicationsDiabetic Nephropathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A